Teva Pharmaceutical (NASDAQ: TEVA) reported Q2 EPS of $1.10, $0.01 better than the analyst estimate of $1.09. Revenue for the quarter came in at $4.21 billion versus the consensus estimate of $4.24 billion.

Earnings